lung cancer | |||||
新闻 | |||||
MEDIAN TECHNOLOGIES (EPA:ALMDT) | Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization.
| |||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
发送反馈 |
No comments:
Post a Comment